Cellular and functional biomarkers of clinical transplant tolerance

2018 ◽  
Vol 79 (5) ◽  
pp. 322-333 ◽  
Author(s):  
James M. Mathew ◽  
Mohammed Javeed Ansari ◽  
Lorenzo Gallon ◽  
Joseph R. Leventhal
2020 ◽  
Vol 21 (1) ◽  
pp. 21-31
Author(s):  
Fadi Issa ◽  
Samuel Strober ◽  
Joseph R. Leventhal ◽  
Tatsuo Kawai ◽  
Dixon B. Kaufman ◽  
...  

2001 ◽  
Vol 33 (7-8) ◽  
pp. 3038-3040
Author(s):  
A.D. Salamam ◽  
M.H. Sayegh

10.1038/8336 ◽  
1999 ◽  
Vol 5 (5) ◽  
pp. 470-471 ◽  
Author(s):  
Kristine Novak

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
James M. Mathew ◽  
Jessica H. Voss ◽  
Scott T. McEwen ◽  
Iwona Konieczna ◽  
Arjun Chakraborty ◽  
...  

2016 ◽  
Vol 77 ◽  
pp. 68
Author(s):  
James M. Mathew ◽  
Jessica L. Heinrichs ◽  
Scott T. McEwen ◽  
Iwona M. Konieczna ◽  
Xuemei Huang ◽  
...  

2018 ◽  
Vol 79 (5) ◽  
pp. 266-271 ◽  
Author(s):  
John D. Scandling ◽  
Stephan Busque ◽  
Robert Lowsky ◽  
Judith Shizuru ◽  
Asha Shori ◽  
...  

2018 ◽  
Vol 79 (5) ◽  
pp. 255-257 ◽  
Author(s):  
James M. Mathew ◽  
Joseph R. Leventhal

2020 ◽  
Vol 26 (42) ◽  
pp. 7655-7671 ◽  
Author(s):  
Jinfeng Zou ◽  
Edwin Wang

Background: Precision medicine puts forward customized healthcare for cancer patients. An important way to accomplish this task is to stratify patients into those who may respond to a treatment and those who may not. For this purpose, diagnostic and prognostic biomarkers have been pursued. Objective: This review focuses on novel approaches and concepts of exploring biomarker discovery under the circumstances that technologies are developed, and data are accumulated for precision medicine. Results: The traditional mechanism-driven functional biomarkers have the advantage of actionable insights, while data-driven computational biomarkers can fulfill more needs, especially with tremendous data on the molecules of different layers (e.g. genetic mutation, mRNA, protein etc.) which are accumulated based on a plenty of technologies. Besides, the technology-driven liquid biopsy biomarker is very promising to improve patients’ survival. The developments of biomarker discovery on these aspects are promoting the understanding of cancer, helping the stratification of patients and improving patients’ survival. Conclusion: Current developments on mechanisms-, data- and technology-driven biomarker discovery are achieving the aim of precision medicine and promoting the clinical application of biomarkers. Meanwhile, the complexity of cancer requires more effective biomarkers, which could be accomplished by a comprehensive integration of multiple types of biomarkers together with a deep understanding of cancer.


Sign in / Sign up

Export Citation Format

Share Document